semaglutide and parkinson's A GLP1 receptor agonist diabetes drug ameliorates neurodegeneration in a mouse model of infantile neurometabolic disease GLP-1 drug shows little benefit

A Phase 2 RCT published in NEJM 2023 reported a mean body weight reduction of approximately 24% at 48 weeks with the 12 mg weekly dose in adults with obesity

GHRP-6 has shown potential in several applications within testing and was the first of its GHRP family to be tested on subjects with various conditions

PARP-1 mediated cell death is directly activated by ZIKV infection

Commonwealth Periodontics and Implant Center is ready to help patients maintain oral health even while managing complex medical treatments

One analysis determined that participants who stopped taking GLP1-drugs had regained about two-thirds of their previous weight loss after one year